EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY 4.0

A Scoping Review on Recent Advances in Antidiabetic Medications: From GLP-1 Receptor Agonists to Dual and Triple Agonists

Gulali Aktas

Advances in Clinical Pharmacology and Therapeutics · 2025

DOI: 10.63623/8cv4gh26 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Advances in Clinical Pharmacology and Therapeutics, 2025. Verfasst von Gulali Aktas. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The management of type 2 diabetes mellitus (T2DM) has evolved substantially with the development of incretin-based therapies targeting the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide (GIP) receptor, and glucagon receptor. This review provides a comprehensive overview of the mechanisms, clinical efficacy, and therapeutic relevance of GLP-1 receptor agonists (GLP-1 RAs), dual GLP-1/GIP receptor agonists, and emerging triple agonists targeting GLP-1, GIP, and glucagon receptors. GLP-1 RAs, now well-established in clinical practice, offer robust glycemic control, weight reduction, and proven cardiovascular and renal benefits through glucose-dependent insulinotropic effects, appetite suppression, and cardiometabolic protection. Dual agonists, such as tirzepatide, expand upon these benefits by simultaneously activating the GIP receptor, yielding superior glycemic efficacy and unprecedented weight loss, alongside potential insulin-sensitizing effects. The latest innovation, triple agonists like retatrutide, incorporate glucagon receptor activation to further enhance energy expenditure, fat loss, and metabolic flexibility, with promising early results in obesity, diabetes, and nonalcoholic fatty liver disease. Together, these agents represent a significant therapeutic advancement in T2DM, with increasing potential for comprehensive cardiometabolic disease management. This review summarizes current evidence from clinical trials and mechanistic studies, discusses comparative benefits, and highlights future directions for optimizing their clinical use.

Zitieren

APA

Aktas, G. (2025). A Scoping Review on Recent Advances in Antidiabetic Medications: From GLP-1 Receptor Agonists to Dual and Triple Agonists. Advances in Clinical Pharmacology and Therapeutics. https://doi.org/10.63623/8cv4gh26

Vancouver

Aktas G. A Scoping Review on Recent Advances in Antidiabetic Medications: From GLP-1 Receptor Agonists to Dual and Triple Agonists. Advances in Clinical Pharmacology and Therapeutics. 2025. doi:10.63623/8cv4gh26

BibTeX
@article{Aktas2025,
  author = {Aktas, Gulali},
  title = {A Scoping Review on Recent Advances in Antidiabetic Medications: From GLP-1 Receptor Agonists to Dual and Triple Agonists},
  journal = {Advances in Clinical Pharmacology and Therapeutics},
  year = {2025},
  doi = {10.63623/8cv4gh26}
}
Kostenlos starten →